## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.8% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($327.46)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. Don't Ignore The Insider Selling In Cencora**
- Source: Simply Wall Street | 20251221T120800 | Somewhat-Bearish | Relevance: 100%
- A Cencora (NYSE:COR) Senior VP recently sold US$1.4m worth of company stock at US$343 per share, representing a 19% decrease in their holding. While there were no insider purchases in the last year, Cencora exhibits strong insider ownership, profits, and growth. Investors should be aware of this selling activity, balanced against the company's positive financials and insider ownership stake, and consider the associated warning signs.

**2. Patton Fund Management Inc. Trims Position in Cencora, Inc. $COR**
- Source: MarketBeat | 20251223T124156 | Somewhat-Bullish | Relevance: 100%
- Patton Fund Management Inc. significantly reduced its stake in Cencora, Inc. by 91.8% in Q3, selling 10,339 shares and retaining 927 shares valued at $290,000. Cencora (NYSE: COR) recently beat Q3 earnings estimates with EPS of $3.84 and revenue of $83.73 billion, while also raising its quarterly dividend to $0.60 per share. The company has a consensus analyst rating of "Moderate Buy" with an average price target of $373.25.

**3. Cencora (NYSE:COR) CEO Robert Mauch Sells 5,096 Shares**
- Source: MarketBeat | 20251223T060816 | Neutral | Relevance: 100%
- Cencora CEO Robert Mauch sold 5,096 shares of the company's stock on December 18th for over $1.75 million, reducing his stake by 6.97%. This transaction follows Cencora's recent financial performance, including beating EPS estimates and raising its quarterly dividend. The stock currently holds a "Moderate Buy" consensus rating from analysts.

**4. Insider Sell Alert: Silvana Battaglia Sells Shares of Cencora In**
- Source: GuruFocus | 20251223T002417 | Somewhat-Bearish | Relevance: 100%
- Silvana Battaglia, Executive Vice President of Cencora Inc, sold 1,677 shares of Cencora Inc (COR) on December 19, 2025, reducing her holdings to 18,796.464 shares. This transaction is part of a pattern observed over the past year, with 30 insider sells and no buys for the company. Cencora Inc's stock is currently trading at $345, making it modestly overvalued according to its GuruFocus Value of $275.51.

**5. Cencora CEO Mauch sells $1.75m in shares By Investing.com**
- Source: Investing.com South Africa | 20251222T220826 | Somewhat-Bullish | Relevance: 100%
- Cencora President and CEO Robert P. Mauch sold 5,096 shares of company stock for $1.75 million on December 18, 2025, while also exercising options to acquire 3,763 shares. These transactions leave Mauch with 68,059 directly owned shares. The company recently announced plans to acquire the remaining stake in OneOncology for approximately $5 billion, a move that has led several analyst firms to raise their price targets for Cencora.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $400 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.2% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.81 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $66.1B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.81 |
| Forward P/E | 17.5 |
| Current P/E | 19.4 |
| YoY Growth | 11.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.6% to -2.8% (-2.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.8pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). MACD histogram bearish (-1.04), momentum weakening. RSI neutral at 44. OFD pattern: +MLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.81% (CS: 25) | Weak |
| RSI_14 | 44.0 | Neutral |
| MACD Histogram | -1.04 | Bearish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 0.983x | Below |
| vs SMA200 | 1.121x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $340.68
- **Stop Loss:** $327.46 (3.9% risk)
- **Target:** $353.90 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 90
- **Position Value:** $30,661.20
- **Portfolio %:** 30.66%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*